Comparison between heparin-conjugated fibrin and collagen sponge as bone morphogenetic protein-2 carriers for bone regeneration

Experimental and Molecular Medicine

Volumn 44, Issue 5, 2012, Pages 350-355

  Yang, Hee Seok ^a   La, Wan Geun ^a   Cho, Yong Min ^a   Shin, Wangsoo ^b   Yeo, Guw Dong ^b   Kim, Byung Soo ^a,b  

^a Seoul National University   (South Korea)

^b Samyang Corporation   (South Korea)

Author keywords

Bone morphogenetic protein 2; Collagen; Drug delivery systems; Fibrin; Osteogenesis

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN SPONGE; DRUG CARRIER; HEPARIN CONJUGATED FIBRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE DENSITY; BONE REGENERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; ENCAPSULATION; ENZYME ACTIVITY; HISTOPATHOLOGY; IN VITRO STUDY; INTERMETHOD COMPARISON; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEWBORN; NONHUMAN; OSSIFICATION; OSTEOMETRY; RAT; SUSTAINED DRUG RELEASE; TREATMENT DURATION;

EID: 84861623467     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2012.44.5.039     Document Type: Article

References (23)

1. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2008;2:81-96
2. Boerckel JD, Kolambkar YM, Dupont KM, Uhrig BA, Phelps EA, Stevens HY, García AJ, Guldberg RE. Effects of protein dose and delivery vehicle on BMP-mediated bone regeneration. Biomaterials 2011;32:5241-51
3. Carter TG, Brar PS, Tolas A, Beirne OR. Off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for reconstruction of mandibular bone defects in humans. J Oral Maxillofac Surg 2008;66:1417-25
4. Derner R, Anderson AC. The bone morphogenic protein. Clin Podiatr Med Surg 2005;22:607-18
5. Friedlaender G. Osteogenic protein-1 in treatment of tibial nonunions: current status. Surg technol int 2004;13:249-52
6. Fu YC, Nie H, Ho ML, Wang CK, Wang CH. Optimized bone regeneration based on sustained release from threedimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2. Biotechnol Bioeng 2008;99:996-1006
7. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: current challenges in BMP delivery. Biotechnol Lett 2009;31:1817-24
8. Issa JP, Bentley MV, Iyomasa MM, Sebald W, De Albuquerque RF. Sustained release carriers used to delivery bone morphogenetic proteins in the bone healing process. Anat Histol Embryol 2008;37:181-7
9. Jeon O, Kang SW, Lim HW, Hyung Chung J, Kim BS. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(l-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 2006;27:1598-607
10. Jeon O, Song SJ, Yang HS, Bhang SH, Kang SW, Sung MA, Lee JH, Kim BS. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem Biophys Res Commun 2008;369:774-80
11. Kanakaris NK, Giannoudis PV. Clinical applications of bone morphogenetic proteins: current evidence. J Surg Orthop Adv 2008;17:133-46
12. La WG, Kang SW, Yang HS, Bhang SH, Lee SH, Park JH, Kim BS. The efficacy of bone morphogenetic protein-2 depends on its mode of delivery. Artif Organs 2010;34: 1150-3
13. Lee JH, Kim CS, Choi KH, Jung UW, Yun JH, Choi SH, Cho KS. The induction of bone formation in rat calvarial defects and subcutaneous tissues by recombinant human BMP-2, produced in Escherichia coli. Biomaterials 2010;31: 3512-9
14. Liu HW, Chen CH, Tsai CL, Hsiue GH. Targeted delivery vehicle for juxtacrine signaling growth factor based on rhBMP-2-mediated carrier-protein conjugation. Bone 2006; 39:825-36
15. Mont MA, Ragland PS, Biggins B, Friedlaender G, Patel T, Cook S, Etienne G, Shimmin A, Kildey R, Rueger DC. Use of bone morphogenetic proteins for musculoskeletal applications: an overview. J Bone Joint Surg Am 2004;86: 41-55
16. Patel ZS, Young S, Tabata Y, Jansen JA, Wong MEK, Mikos AG. Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone 2008;43:931-40
17. Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, Harpring J, Shields CB. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006;31: 542-7
18. Takahashi Y, Yamamoto M, Tabata Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and β-tricalcium phosphate. Biomaterials 2005;26:4856-65
19. Termaat MF, Den Boer FC, Bakker FC, Patka P, Haarman HJ. Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am 2005;87:1367-78
20. Uludag H, D'Augusta D, Palmer R, Timony G, Wozney J. Characterization of rhBMP 2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res 1999;46:193-202
21. Yang HS, La WG, Bhang SH, Jeon JY, Lee JH, Kim BS. Heparin-conjugated fibrin as an injectable vehicle for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A 2010;16:1225-33
22. Yang HS, La WG, Bhang SH, Kim HJ, Im GI, Lee H, Park JH, Kim BS. Hyaline cartilage regeneration by combined therapy of microfracture and long-term bone morphogenetic protein-2 delivery. Tissue Eng Part A 2011;17:1809-18
23. Zhao B, Katagiri T, Toyoda H, Takada T, Yanai T, Fukuda T, Chung UI, Koike T, Takaoka K, Kamijo R. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 2006;281:23246-53